Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) SVP Sells 1,404 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURA) SVP Amy Elazzouzi sold 1,404 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total transaction of $10,881.00. Following the completion of the sale, the senior vice president now owns 82,278 shares of the company’s stock, valued at approximately $637,654.50. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Amy Elazzouzi also recently made the following trade(s):

• On Tuesday, January 21st, Amy Elazzouzi sold 1,001 shares of Aura Biosciences stock. The shares were sold at an average price of $7.67, for a total transaction of $7,677.67.

Aura Biosciences Stock Down 3.8 %

Shares of AURA stock opened at $7.65 on Wednesday. Aura Biosciences, Inc. has a 52 week low of $6.63 and a 52 week high of $12.38. The stock has a market capitalization of $382.12 million, a PE ratio of -4.42 and a beta of 0.29. The firm has a 50 day moving average of $8.07 and a two-hundred day moving average of $8.76.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Aura Biosciences currently has a consensus rating of “Buy” and a consensus target price of $23.00.

Hedge Funds Weigh In On Aura Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets purchased a new position in Aura Biosciences in the 4th quarter valued at approximately $50,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Aura Biosciences during the 4th quarter worth $87,000. ProShare Advisors LLC purchased a new stake in shares of Aura Biosciences during the 4th quarter worth $127,000. Harvest Investment Services LLC purchased a new stake in shares of Aura Biosciences during the 4th quarter worth $133,000. Finally, AlphaQuest LLC purchased a new stake in shares of Aura Biosciences during the 4th quarter worth $136,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.